Use of cardiovascular medications linked to fall risk in older adults

NewsGuard 100/100 Score

A new analysis suggests that among older adults who take cardiovascular medications, those using non-selective beta-blockers may be at an increased of falling compared with those using selective beta-blockers. These types of drugs are already known to differ by their receptor binding properties and their systemic effects on the body.

In the analysis of data from 2 prospective studies involving more than 10,000 individuals, use of a selective beta-blocker was not associated with fall risk, but use of a non-selective beta-blocker was associated with a 22% increased risk. In total, 2,917 participants encountered a fall during follow-up.

The results indicate that fall risk should be considered when weighing the pros and cons of prescribing different beta-blocker classes for older individuals.

"Drug-related falls remain under-recognized, leading to preventable falls and related injury. Precise prediction of drug-related fall risk is of major importance for clinical decision-making," said Dr. Nathalie van der Velde, senior author of the British Journal of Clinical Pharmacology study. "Knowledge of type-specific effects such as selectivity in beta-blockers can be expected to improve decision-making."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Navigating the complexities of controlled release drug formulations